Efficacy

Monjuvi (tafasitamab-cxix) for Lymphoma

Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This medication is not intended for use in patients with primary central nervous system lymphoma. The efficacy of Monjuvi, in combination with lenalidomide, was evaluated in a multicenter, single-arm, open-label trial known as L-MIND. In this study, patients who received Monjuvi in combination with lenalidomide showed a significant improvement in overall response rate (ORR), with a considerable proportion of patients achieving a complete response (CR).

The L-MIND trial demonstrated that the median duration of response (DOR) for patients treated with the Monjuvi and lenalidomide combination was 21.7 months. The median time to response was 2 months, and the treatment was generally well-tolerated, with manageable adverse effects. This data underscores the potential of Monjuvi as an effective treatment option for patients with relapsed or refractory DLBCL, particularly for those who have limited treatment options.

Ukoniq (umbralisib) for Lymphoma

Ukoniq (umbralisib) is a kinase inhibitor approved for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies. The efficacy of Ukoniq was primarily demonstrated in a multicenter, open-label, single-arm trial known as the UNITY-NHL trial. In this study, patients with MZL treated with Ukoniq achieved an ORR of 49%, with a median DOR of not reached at the time of data cut-off, indicating a durable response in a significant number of patients.

Similarly, patients with FL who received Ukoniq showed an ORR of 43%, with a median DOR also not reached at the time of data cut-off. These efficacy results suggest that Ukoniq is a beneficial treatment for patients with MZL and FL, especially for those who have exhausted multiple lines of therapy. The treatment was associated with a manageable safety profile, although patients should be monitored for potential adverse effects that may require dose modifications or discontinuation of therapy.